NCT01744223 · ClinicalTrials.gov record · last posted 2022-07-12
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
StatusActive, Not Recruiting
PhasePhase 1/2
Started2013-03
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the laboratory and then given back to the patient along with the stem cell transplant (T cell addback), can help the immune system recover faster after the transplant. As a safety measure, these T cells have been "programmed" with a "self-destruct switch" so that if, after they have been given to the patient, the T cells start to react against the tissues (called "graft versus host" disease, GVHD), the T cells can be destroyed.
Amendment record
26 amendments on the ClinicalTrials.gov record
This ClinicalTrials.gov record has been amended 26 times since 2012-12-05; most recent amendment 2022-07-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history.
See every version on ClinicalTrials.gov ↗
2018-09-27
Status change Recruiting→Active, Not Recruitingv19
2013-03-20
Status change Not Yet Recruiting→Recruitingv1
| NCT Number |
NCT01744223 |
| Lead Sponsor |
Bellicum Pharmaceuticals
|
| Conditions |
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes |
| Enrollment |
36 participants |
| Start Date |
2013-03 |
| Primary Completion |
2019-10-09 (estimated) |
| Study Completion |
2032-10 (estimated) |
| Updated on ClinicalTrials.gov |
2022-07-12 |